TSC-201

N/A

Report date: 2024/04/28 11:22:41

Base Information

Drug NameTSC-201
Drug Alias NameTSC-201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma-associated antigen C2 modulators
TargetsMelanoma-associated antigen C2
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A